Supplementation with cholecalciferol during pregnancy linked to increased bone mineral content, bone mineral density, lean mass in offspring ...

The Company is seeking approval of tirzepatide for the treatment of HFpEF and obesity and has submitted data to the FDA. Detailed results were announced from a phase 3 clinical trial evaluating the ...

Source: Getty Images “The potential adverse impact of chemotherapy exposure during pregnancy is likely mediated through ...

Researchers analyzed whole-genome sequencing data from 76,805 patients to identify variants in 4 genes that are associated ...

The Food and Drug Administration (FDA) has expanded the approval of Nerivio ® (Theranica) to include the acute and/or ...

One year after reports of supply chain issues, 49% of reports in the US and 34% of reports in Canada were associated with ...

Danziten is a twice daily, oral medication that inhibits the BCR-ABL tyrosine kinase. Nilotinib was originally approved under the brand name Tasigna; it is currently indicated for adults and pediatric ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...

The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.